FHL蛋白与肺动脉高压研究进展

FHL（four-and-a-half-LIM domain）是含4（1/2）个LIM结构域富含半胱氨酸的细胞骨架蛋白,LIM是一种在C.elegans线虫的Lin-1和Mec-3基因及大鼠Isl-1基因编码的DNA结合蛋白中分离鉴定出来的基因序列,LIM取三个基因的首字母而成。FHL家族含FHL-1-5五个成员,而FHL-1-3最早发现在心脏的发育过程中起重要作用,后面发现在肺动脉高压中有促进增殖、迁移等作用。本文就FHL家族和肺动脉高压关系作一综述,阐明FHL蛋白在PH进程中的重要作用。     

FHL家族功能研究进展

FHL是含有4个半LIM结构域的蛋白家族,体内现已发现5个成员,即FHL1、FHL2、FHL3、FHL4、FHL5/ACT,不同成员在组织中表达具有特异性。FHL家族通过LIM结构域与其他蛋白质相互作用,在各种肌细胞的生长与分化、肿瘤的发生发展以及基因的转录调节中发挥重要的作用。     

FHL1的结构和功能及其与疾病的关系

FHL（four and a half LIM domain）家族是含有4 个半LIM结构域的蛋白家族,现发现该家族由5 个成员,即FHL1、FHL2、FHL3、FHL4、FHL5 /ACT 组成,其表达具有组织特异性.它们通过LIM结构域与某些结构蛋白、激酶、转录调控因子等多种蛋白质相互作用,对某些基因的表达、细胞分化与发育、细胞骨架形成等发挥重要调控作用.FHL1（four and a half LIM domain 1）是FHL家族中表达最广泛的成员,尤其在骨骼肌和心肌中高表达.近年研究表明其参与某些病理过程,与心血管疾病、肌肉疾病、肿瘤疾病等相关.     

LIM—only转录因子研究进展

LIM—only转录因子是LIM基因家族中的LIM—only基因编码的转录调节因子,其蛋白(LMO蛋白)结构中含1个或多个LIM结构域。LIM结构域由两个串联重复的种间高度保守的LIM基元组成。现已发现属于该家族的基因主要有LMO1、LMO2、LMO3、LMO4、dLMO、XLMO、PDLP、FHL等,并且还会有新的发现。迄今的研究结果表明,LMO蛋白是一种蛋白相互作用的适配器,它的LIM结构域可与核内广泛分布的LIM结构域结合蛋白或其他的转录调节因子结合形成转录复合体,启动特异基因的转录,调节生物的发育和分化,并与肿瘤的形成有关。     

FHL家族研究进展

FHL（four and a half LIM domain）家族是含有4个半LIM结构域的蛋白家族,现发现该家族由5个成员,即FHL1、FHL2、FHL3、FHL4、FHL5／ACT组成,其表达具有组织特异性。简要介绍了FHL家族的组织分布、相互作用蛋白,及其在转录调节、肌细胞生长与分化、肿瘤发生发展中的作用。     

FHL2 蛋白在肿瘤中的转录调控及其分子生物学机制

FHL2是仅有四个半LIM结构域(FHL)蛋白家族的成员,目前在FHL蛋白家族中研究最为广泛。FHL2作为重要的衔接蛋白和支架蛋白,主要通过LIM结构域介导蛋白分子间的相互作用以实现其生物学功能。Fhl2基因在转录水平受多种肿瘤相关基因的调控,如p53,血清应答因子等。FHL2与恶性肿瘤的关系是近年来的研究热点,目前认为FHL2能够作为癌蛋白及抑癌蛋白通过不同机制广泛影响乳腺癌、胃肠道肿瘤、肝癌、前列腺癌等肿瘤的发生发展,并且在不同肿瘤中的表达具有组织特异性。本文就FHL2的结构特点、功能、转录调控及与肿瘤的关系几个方面展开综述,从而明确FHL2在不同肿瘤中所发挥的作用及其分子生物学机制将会为治疗相关肿瘤提供新的干预靶点。     

FHL2转录激活结构域的定位

LIM蛋白家族成员FHL2 (fourandhalfLIMdomainprotein)在转录调节、细胞凋亡及肿瘤的发生发展中都起着重要作用。利用GAL4转录因子中的DNA结合结构域 (DBD)和含有与DBD结合序列的荧光素酶报告基因(GAL4 LUC)构建了哺乳动物细胞转录激活系统 ,并利用该系统定位了FHL2的转录激活结构域。首先将GAL4 DBD序列以正确读框插入到pcDNA3载体的多克隆位点中 ,构建成真核表达载体pDBD ,再将野生型FHL2及其不同片段以正确读框与pDBD中GAL4 DBD序列融合 ,构建成野生型FHL2及其缺失突变体表达载体。将这些表达载体分别瞬时转染 2 93T胚胎肾细胞 ,野生型FHL2及其缺失突变体都得到了表达。利用GAL4 荧光素酶报告基因对野生型FHL2及其不同突变体的转录激活活性检测表明 ,在 2 93T胚胎肾细胞和乳腺癌MCF 7细胞中 ,野生型FHL2具有转录激活活性 ,缺失N端半个LIM结构域使FHL2转录激活活性降低 ,缺失C末端第二个LIM结构域对FHL2的转录激活功能影响不大 ,缺失C末端最后一个LIM结构域则使FHL2的转录激活功能完全丧失 ,而C末端缺失 2个LIM结构域使FHL2转录激活活性又有所恢复。这说明FHL2C末端最后一个LIM结构域对其转录激活功能是必需的 ,而C末端第二个LIM结构域可能对FHL2的转录激活功能有负调控作用 ,这种负调控作用取决于     

BRCA1相互作用蛋白的分离及鉴定

乳腺癌易感基因(breast cancer susceptibility gene-1,BRCAl)在DNA损伤修复、细胞周期调控、染色质的稳定、基因转录激活以及细胞凋亡等方面起着重要作用。BRCAI C-末端是富含酸性氨基酸的转录激活结构域(AD),AD核心结构为两个串联的BRCT结构域(BRCTl和BRCT2)。应用酵母双杂交技术,以BRCT2为诱饵蛋白,从卵巢文库中筛选到了与BRCT2结构域相互作用蛋白FHL2(four and half LIM domains)。利用酵母交配的方法证明FHL2与BRCAlBRCT2特异结合,而不与BRCAl BRCTl、Rapl BRCT结构域结合。GST沉淀实验表明,FHL2在体外特异地与BRCT2结构域相结合;免疫共沉淀实验表明,FHL2在体内特异地与BRCT2结构域结合;FHL2可与全长BRCAl结合。BRCAl与FHL2相互作用的发现为研究BRCAl以及FHL2在肿瘤发生、发展中的作用打下了坚实的基础。     

FHL2通过相互作用抑制分化抑制蛋白家族成员的转录抑制活性

目的：探讨FHL2与Id（分化抑制蛋白）家族蛋白之间的相互作用及FHL2对Id蛋白功能的调控效应。方法：用GST-pulldown与免疫共沉淀（CoIP）方法检测FHL2与Id家族蛋白成员之间在体内外的相互作用;用共转染与报告基因驱动的萤光素酶方法检测FHL2对Id蛋白介导转录抑制效应的调控作用。结果：FHL2与Id家族的4个蛋白均存在直接的相互作用关系,表位分析结果显示FHL2蛋白中的第2个LIM结构域在FHL2/Id相互作用中是必需的,Id蛋白N端结构域在介导FHL2/Id相互作用中是必需的,FHL2/Id相互作用不依赖于Id蛋白中的螺旋-环-螺旋结构;通过相互作用,FHL2阻止了Id蛋白对碱性螺旋-环-螺旋转录因子E47转录活性的抑制作用。结论：FHL2是一个新识别的Id蛋白广谱的相互作用因子,通过对Id蛋白功能活性的抑制效应,FHL2可能参与Id介导的多种生物学效应以及肿瘤发生与进展。     

FHL家族与肿瘤的关系

FHL（four and half LIM domains）是LIM-only蛋白家族的重要成员。FHL家族包括FHLl-FHL5共5个成员,它们具有组织特异性。研究发现,FHL参与转录调节、信号转导、凋亡等,是细胞生长、分化的重要调节因子。已证实FHLl、FHL2与不同组织来源肿瘤的发生和发展有关。FHL表达水平是某些肿瘤预后的相关因素。研究FHL与肿瘤的关系,有利于阐明肿瘤的病理生理机制。     

Protein-protein interaction of FHL3 with FHL2 and visualization of their interaction by green fluorescent proteins (GFP) two-fusion fluorescence resonance energy transfer (FRET)

LIM domain proteins are found to be important regulators in cell growth, cell fate determination, cell differentiation and remodeling of the cell cytoskeleton. Human Four-and-a-half LIM-only protein 3 (FHL3) is a type of LIM-only protein that contains four tandemly repeated LIM motifs with an N-terminal single zinc finger (half LIM motif). FHL3 expresses predominantly in human skeletal muscle. In this report, FHL3 was shown to be a novel interacting partner of FHL2 using the yeast two-hybrid assay. Furthermore, site-directed mutagenesis of FHL3 indicated that the LIM2 of FHL3 is the essential LIM domain for interaction with FHL2. Green fluorescent protein (GFP) was used to tag FHL3 in order to study its distribution during myogenesis. Our result shows that FHL3 was localized in the focal adhesions and nucleus of the cells. FHL3 mainly stayed in the focal adhesion during myogenesis. Moreover, using site-directed mutagenesis, the LIM1 of FHL3 was identified as an essential LIM domain for its subcellular localization. Mutants of GFP have given rise to a novel technique, two-fusion fluorescence resonance energy transfer (FRET), in the determination of protein-protein interaction at particular subcellular locations of eukaryotic cells. To determine whether FHL2 and FHL3 can interact with one another and to locate the site of this interaction in a single intact mammalian cell, we fused FHL2 and FHL3 to different mutants of GFP and studied their interactions using FRET. BFP/GFP fusion constructs were cotransfected into muscle myoblast C2C12 to verify the colocalization and subcellular localization of FRET. We found that FHL2 and FHL3 were colocalized in the mitochondria of the C2C12 cells and FRET was observed by using an epi-fluorescent microscope equipped with an FRET specific filter set.     

The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle

We have determined the complete mRNA sequence of FHL3 (formerly SLIM2). We have confirmed that it is a member of the family of LIM proteins that share a similar secondary protein structure, renamed as Four-and-a-Half-LIM domain (or FHL) proteins in accordance with this structure. The "half-LIM" domain is a single zinc finger domain that may represent a subfamily of LIM domains and defines this particular family of LIM proteins. The distribution of FHL mRNA expression within a variety of murine tissues is complex. Both FHL1 and FHL3 were expressed in a number of skeletal muscles while FHL2 was expressed at high levels in cardiac muscle. Localisation of FHL3 to human chromosome 1 placed this gene in the proximity of, but not overlapping with, alleles associated with muscle diseases. FHL1 and FHL3 mRNAs were reciprocally expressed in the murine C2C12 skeletal muscle cell line and this suggested that the pattern of expression was linked to key events in myogenesis.     

Identification of the transactivation domain of the human FHL3

Four and a half LIM domain protein 3 (FHL3) has the transactivation and repressor activity, and plays important roles in regulating the expression levels of various genes. In this study, FHL3 was proved to possess the auto-activation ability when constructed into the pGBKT7 plasmid (a GAL4 DNA-binding domain (BD) cloning vector of the yeast two-hybrid system) and transformed into yeast Y190 cells. To determine the transactivation domain of FHL3, five mutants were constructed by sequentially deleting each LIM domain of FHL3 and then inserting them into the pGBKT7 plasmid. After being transformed into yeast Y190 cells, expression levels of the mutants were identified by Western blot analysis. The β-galactosidase assay showed that the mutant without the fourth LIM domain (LIM4) lost the auto-activation ability. Further investigations on the mutants with deleted first or second zinc finger of LIM4 confirmed that the second zinc finger motif in LIM4 was responsible for the auto-activation of FHL3.     

The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor

FHL1, FHL2, and FHL3 are members of the four and one-half LIM domain protein subclass that are expressed in striated muscles. Here we show that FHL2 and FHL3 are novel alpha(7)beta(1) integrin-interacting proteins. They bind both the alpha- and the beta-subunit as well as different splice isoforms. The minimal binding sites for FHL2 and FHL3 on beta(1A)-chain overlap, whereas on alpha(7A) and alpha(7B) subunits they are situated adjacent. Determining the binding sites for integrins on FHL2 or FHL3 revealed that the suprastructure of the whole molecule is important for these associations, rather than any single LIM domain. Immunofluorescence studies with cells expressing full-length FHL proteins or their deletion mutants showed that FHL2 and FHL3 but not FHL1 colocalize with integrins at cell adhesion sites. Further, their recruitment to the membrane results from binding to either the alpha- or the beta-chain of the integrin receptor. The association of FHL2 or FHL3 with integrin receptors neither influences attachment of cells to different substrates nor changes their migration capacity. However, in cardiac and skeletal muscles, FHL2 and FHL3, respectively, are colocalized with alpha(7)beta(1) integrin receptor at the periphery of Z-discs, suggesting a role in mechanical stabilization of muscle cells.     

An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1

We have identified a large multigenerational Austrian family displaying a novel form of X-linked recessive myopathy. Affected individuals develop an adult-onset scapulo-axio-peroneal myopathy with bent-spine syndrome characterized by specific atrophy of postural muscles along with pseudoathleticism or hypertrophy and cardiac involvement. Known X-linked myopathies were excluded by simple-tandem-repeat polymorphism (STRP) and single-nucleotide polymorphism (SNP) analysis, direct gene sequencing, and immunohistochemical analysis. STRP analysis revealed significant linkage at Xq25-q27.1. Haplotype analysis based on SNP microarray data from selected family members confirmed this linkage region on the distal arm of the X chromosome, thereby narrowing down the critical interval to 12 Mb. Sequencing of functional candidate genes led to the identification of a missense mutation within the four and a half LIM domain 1 gene (FHL1), which putatively disrupts the fourth LIM domain of the protein. Mutation screening of FHL1 in a myopathy family from the UK exhibiting an almost identical phenotype revealed a 3 bp insertion mutation within the second LIM domain. FHL1 on Xq26.3 is highly expressed in skeletal and cardiac muscles. Western-blot analysis of muscle biopsies showed a marked decrease in protein expression of FHL1 in patients, in concordance with the genetic data. In summary, we have to our knowledge characterized a new disorder, X-linked myopathy with postural muscle atrophy (XMPMA), and identified FHL1 as the causative gene. This is the first FHL protein to be identified in conjunction with a human genetic disorder and further supports the role of FHL proteins in the development and maintenance of muscle tissue. Mutation screening of FHL1 should be considered for patients with uncharacterized myopathies and cardiomyopathies.